Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

25 trials with published results (25%)

Research Maturity

69 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.0%

3 terminated out of 100 trials

Success Rate

95.8%

+9.3% vs benchmark

Late-Stage Pipeline

24%

24 trials in Phase 3/4

Results Transparency

36%

25 of 69 completed with results

Key Signals

25 with results96% success

Data Visualizations

Phase Distribution

70Total
Not Applicable (19)
Early P 1 (1)
P 1 (12)
P 2 (14)
P 3 (21)
P 4 (3)

Trial Status

Completed69
Recruiting11
Unknown8
Not Yet Recruiting5
Terminated3
Withdrawn2

Trial Success Rate

95.8%

Benchmark: 86.5%

Based on 69 completed trials

Clinical Trials (100)

Showing 20 of 20 trials
NCT05869773Phase 4CompletedPrimary

A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

NCT07540364Phase 3Not Yet RecruitingPrimary

A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy

NCT06179407Phase 1TerminatedPrimary

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

NCT07493265Phase 2Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT06279247RecruitingPrimary

Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

NCT06383806Not ApplicableNot Yet RecruitingPrimary

Decreasing Nightmares in Adults With Narcolepsy

NCT06792708CompletedPrimary

Observational Study of LUMRYZ in Narcolepsy

NCT04806620Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT02799849Not ApplicableCompletedPrimary

Metabolism Characteristics in the Children With Narcolepsy

NCT07051252Phase 1CompletedPrimary

A Study of HBS-201 (Pitolisant Delayed-release)

NCT05113745Phase 3CompletedPrimary

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT04451668Phase 3CompletedPrimary

An Open Label Study of FT218 in Subjects With Narcolepsy

NCT06961266Phase 1RecruitingPrimary

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

NCT05536011Recruiting

WAKIX® (Pitolisant) Pregnancy Registry

NCT05875974Phase 4Completed

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

NCT05371483Enrolling By InvitationPrimary

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments

NCT05059223Phase 3CompletedPrimary

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

NCT03267303Phase 2CompletedPrimary

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy

NCT04141891Not ApplicableCompleted

Advancing Understanding of Transportation Options

NCT06797284Not ApplicableRecruiting

The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders

Scroll to load more

Research Network

Activity Timeline